Davis R M Inc. Has $555,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Davis R M Inc. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 6,859 shares of the medical equipment provider’s stock after selling 480 shares during the period. Davis R M Inc.’s holdings in Hologic were worth $555,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Hologic by 98,061.1% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 22,086,241 shares of the medical equipment provider’s stock worth $1,788,323,000 after purchasing an additional 22,063,741 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after buying an additional 4,363,687 shares during the last quarter. Wellington Management Group LLP boosted its stake in Hologic by 80.0% in the first quarter. Wellington Management Group LLP now owns 8,984,757 shares of the medical equipment provider’s stock valued at $725,070,000 after buying an additional 3,992,822 shares in the last quarter. Norges Bank bought a new position in Hologic in the fourth quarter valued at about $175,900,000. Finally, Envestnet Asset Management Inc. raised its stake in Hologic by 506.3% during the first quarter. Envestnet Asset Management Inc. now owns 1,711,592 shares of the medical equipment provider’s stock worth $29,345,000 after acquiring an additional 1,429,300 shares in the last quarter. 92.64% of the stock is owned by institutional investors.

Hologic Stock Performance

NASDAQ:HOLX opened at $71.90 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.95 and a current ratio of 3.47. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The company has a 50 day simple moving average of $69.42 and a two-hundred day simple moving average of $75.31. The company has a market capitalization of $17.61 billion, a PE ratio of 39.29, a P/E/G ratio of 2.34 and a beta of 1.03.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, November 9th. The medical equipment provider reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.05. Hologic had a net margin of 11.31% and a return on equity of 19.12%. The company had revenue of $945.30 million for the quarter, compared to analyst estimates of $940.00 million. The company’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.82 EPS. Research analysts anticipate that Hologic, Inc. will post 3.99 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on HOLX. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, November 10th. TheStreet downgraded shares of Hologic from a “b” rating to a “c+” rating in a report on Monday, July 31st. Needham & Company LLC cut their price objective on Hologic from $95.00 to $83.00 and set a “buy” rating on the stock in a report on Thursday, October 26th. UBS Group lowered their target price on Hologic from $91.00 to $78.00 and set a “neutral” rating for the company in a report on Thursday, November 16th. Finally, Citigroup dropped their target price on Hologic from $90.00 to $85.00 and set a “neutral” rating for the company in a research report on Tuesday, August 1st. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.58.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.